Ependymoma
Posterior fossa group A and ZFTA-fusion tumours, where surgery and radiotherapy remain the only standard.
Each dot is one target. Higher means stronger genetic evidence in people (inherited variants or tumour mutations, whichever is stronger). Further right means more evidence from drugs already in trials or approved.
Scores run from 0 to 1 and are Open Targets' summary of how much evidence exists, not the chance a drug will work. The dividing lines sit at 0.5. Hover a dot for its numbers, click it for the target's page. Source: Open Targets Platform, fetched live.
The 7 targets in the top-left of the chart, strongest genetic evidence first. Click one for its drugs, tractability and other cancers.
All 50 targets, by type of evidence
Ranked by overall score for ependymoma on the Open Targets Platform. Darker cells mean stronger evidence of that type.
Peds RMTLmarks the 9 of these targets on the FDA's Pediatric Relevant Molecular Target List: a drug against one of them can be required to be studied in children under the RACE for Children Act.
| Target | Overall | Germline genetics | Somatic | Literature | RNA expr. | Clinical |
|---|---|---|---|---|---|---|
| NF2 NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor | 0.44 | – | 0.57 | |||
| TSC1 TSC complex subunit 1 | 0.42 | – | 0.68 | |||
| TSC2 TSC complex subunit 2 | 0.38 | – | 0.61 | |||
| TOP2A DNA topoisomerase II alpha | 0.37 | – | – | |||
| GSR glutathione-disulfide reductase | 0.37 | – | – | |||
| TOP2B DNA topoisomerase II beta | 0.37 | – | – | |||
| TUBB4A tubulin beta 4A class IVa | 0.36 | – | – | |||
| TUBA4A tubulin alpha 4a | 0.36 | – | – | |||
| TUBB3 tubulin beta 3 class III | 0.36 | – | – | |||
| TUBA1A tubulin alpha 1a | 0.36 | – | – | |||
| TUBB2B tubulin beta 2B class IIb | 0.36 | – | – | |||
| TUBB2A tubulin beta 2A class IIa | 0.36 | – | – | |||
| TUBB4B tubulin beta 4B class IVb | 0.36 | – | – | |||
| TUBB1 tubulin beta 1 class VI | 0.36 | – | – | |||
| TUBB6 tubulin beta 6 class V | 0.36 | – | – | |||
| TUBB tubulin beta class I | 0.36 | – | – | |||
| TUBA3E tubulin alpha 3e | 0.36 | – | – | |||
| TUBA1C tubulin alpha 1c | 0.36 | – | – | |||
| TUBA3C tubulin alpha 3c | 0.36 | – | – | |||
| TUBB8 tubulin beta 8 class VIII | 0.36 | – | – | |||
| TUBA1B tubulin alpha 1b | 0.36 | – | – | |||
| BRAFPeds RMTL B-Raf proto-oncogene, serine/threonine kinase | 0.35 | – | 0.57 | |||
| PIK3CAPeds RMTL phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | 0.34 | – | 0.45 | |||
| MEN1Peds RMTL menin 1 | 0.34 | – | 0.55 | |||
| MUTYH mutY DNA glycosylase | 0.34 | 0.56 | – | |||
| BCORPeds RMTL BCL6 corepressor | 0.33 | – | 0.53 | |||
| DHFR dihydrofolate reductase | 0.33 | – | – | |||
| FLT4 fms related receptor tyrosine kinase 4 | 0.30 | – | 0.46 | |||
| TP53Peds RMTL tumor protein p53 | 0.30 | – | 0.46 | |||
| ALKPeds RMTL ALK receptor tyrosine kinase | 0.30 | – | 0.46 | |||
| ERBB4 erb-b2 receptor tyrosine kinase 4 | 0.30 | – | 0.46 | |||
| FGFR1 fibroblast growth factor receptor 1 | 0.29 | – | 0.46 | |||
| CDKN2A cyclin dependent kinase inhibitor 2A | 0.29 | – | 0.46 | |||
| IDH1Peds RMTL isocitrate dehydrogenase (NADP(+)) 1 | 0.29 | – | 0.46 | |||
| MAML2 mastermind like transcriptional coactivator 2 | 0.28 | – | 0.46 | |||
| NOTCH1Peds RMTL notch receptor 1 | 0.28 | – | 0.46 | |||
| NTRK3 neurotrophic receptor tyrosine kinase 3 | 0.28 | – | 0.46 | |||
| ASXL1 ASXL transcriptional regulator 1 | 0.28 | – | 0.46 | |||
| PTENPeds RMTL phosphatase and tensin homolog | 0.28 | – | 0.46 | |||
| ESR1 estrogen receptor 1 | 0.28 | – | 0.46 | |||
| FHIT fragile histidine triad diadenosine triphosphatase | 0.28 | – | 0.46 | |||
| FLI1 Fli-1 proto-oncogene, ETS transcription factor | 0.28 | – | 0.46 | |||
| ARHGAP26 Rho GTPase activating protein 26 | 0.28 | – | 0.46 | |||
| HGF hepatocyte growth factor | 0.28 | – | 0.46 | |||
| CRTC1 CREB regulated transcription coactivator 1 | 0.28 | – | 0.46 | |||
| PTPRK protein tyrosine phosphatase receptor type K | 0.28 | – | 0.46 | |||
| TBL1XR1 TBL1X/Y related 1 | 0.28 | – | 0.46 | |||
| LRP1B LDL receptor related protein 1B | 0.28 | – | 0.46 | |||
| WRN WRN RecQ like helicase | 0.28 | – | 0.46 | |||
| PBRM1 polybromo 1 | 0.28 | – | 0.46 |
6 biomarkers in Ependymoma have validated or clinical evidence in CIViC
Accepted evidence from CIViC, the open (CC0) expert-curated knowledgebase, searched by the disease name “Ependymoma”. Level A is validated (for example in guidelines or an approval), level B comes from clinical trials or studies. 21 accepted items exist; the first 21 were read. This is the published evidence, not treatment advice.
- ZFTA::RELA Fusion level A
- Methylation signature ST-EPN-ZFTA level B
- ERBB2 Amplification level B
- ERCC5 RS751402 level B
- YAP1::MAMLD1 Fusion level B
- YAP1::v Fusion level B